ANABAnaptysBio, Inc.

Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, […]

CorMedix (CRMD) delivered earnings and revenue surprises of +11.54% and +7.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing Water Capital returning approximately 39.8% net of all fees and expenses, bringing the YTD return to approximately 33.6% net. […]

Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.

The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Grupo Traxión is in focus after a major global bank cut its MX$ price target by MX$6, pointing to a more restrained view on the stock. The shift lines up with recent research that adopts a more cautious tone on parts of the story, even as some analysts keep a constructive stance. As you read on, you will see how this evolving narrative could shape the way you track and interpret future updates around the stock. Stay updated as the Fair Value for Grupo Traxión. de shifts by adding it to your...

After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.

Conference spotlight after royalty pivot AnaptysBio (ANAB) is set to present at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, following its recent spinoff of First Tracks Biotherapeutics and shift to a royalty focused model. See our latest analysis for AnaptysBio. The stock has had a strong run, with a 90 day share price return of 34.65% and a 1 year total shareholder return of 413.05%. This suggests momentum has been building as investors react to the royalty...

AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. The firm stated that the company announced in April 2026 the completion of the First Tracks […]